48,200 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 48,200 shares of the company's stock, valued at approximately $512,000. Two Sigma Advisers LP owned about 0.06% of Immunome as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of IMNM. Stoneridge Investment Partners LLC bought a new position in shares of Immunome in the 4th quarter valued at $123,000. Three Bridge Wealth Advisors LLC bought a new position in shares of Immunome in the 4th quarter valued at $293,000. Los Angeles Capital Management LLC acquired a new stake in shares of Immunome during the 4th quarter valued at $379,000. Johnson Financial Group LLC acquired a new stake in shares of Immunome during the 4th quarter valued at $212,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Immunome by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company's stock valued at $4,856,000 after acquiring an additional 14,775 shares in the last quarter. Institutional investors own 44.58% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wedbush reissued an "outperform" rating and set a $21.00 price objective (down previously from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Lifesci Capital assumed coverage on Immunome in a report on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price objective on the stock. Guggenheim cut their price objective on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. Stephens reaffirmed an "overweight" rating and set a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Finally, Lake Street Capital assumed coverage on Immunome in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $23.33.

Immunome Trading Up 0.1%

Shares of NASDAQ IMNM traded up $0.01 during midday trading on Friday, hitting $9.13. The company's stock had a trading volume of 1,228,054 shares, compared to its average volume of 920,741. The stock has a fifty day moving average price of $7.88 and a 200 day moving average price of $9.50. The firm has a market capitalization of $794.42 million, a price-to-earnings ratio of -1.13 and a beta of 1.94. Immunome, Inc. has a one year low of $5.15 and a one year high of $16.81.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, equities research analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Insider Activity

In other news, CTO Philip Tsai acquired 12,300 shares of Immunome stock in a transaction on Monday, March 24th. The stock was acquired at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. This trade represents a 58.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime acquired 5,000 shares of Immunome stock in a transaction on Tuesday, June 3rd. The shares were purchased at an average price of $9.38 per share, with a total value of $46,900.00. Following the completion of the purchase, the director now owns 36,415 shares in the company, valued at $341,572.70. This represents a 15.92% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 161,400 shares of company stock valued at $1,207,395. Corporate insiders own 8.60% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.